2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study
Fontaniere, C. De La Fouchardiere, Paule, B., Burtin, P, Wallet, J., Tougeron, D., Dourthe, L.M., Etienne, P.L., Mineur, L., Becuwe, C., Maes, P., Dauba, J., Michel, P., Wendling, J.L., Linot, B., HolVolume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31017-6
Date:
September, 2015
File:
PDF, 60 KB
english, 2015